AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Eastman Kodak today, you really have to believe the company can turn its mix of legacy print, specialty film and newer advanced materials and pharma products into a consistently profitable business. The latest first quarter numbers fit that tension: better sales and revenue, stronger Print and Advanced Materials & Chemicals contributions, but still a wider net loss and losses per share. In the short term, catalysts still sit in execution on new offerings like VERITA 200D, scaling collaborations such as the Ateios RaiCore battery platform, and ramping the regulated pharma portfolio, rather than in any single quarter’s headline result. The Q1 loss keeps profitability risk front and center, and may sharpen investor focus on cash use, recent share price strength and whether higher-margin projects can support the current valuation.
However, one key risk is that continued losses could test confidence in Kodak’s recent share price gains. Eastman Kodak's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Explore 3 other fair value estimates on Eastman Kodak - why the stock might be worth less than half the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com